Nektar Therapeutics [NASDAQ: NKTR] closed the trading session at $242000.0 on 2025-06-24. The day’s price range saw the stock hit a low of $16.56, while the highest price level was $27.68.
The stocks have a year to date performance of 49.54 percent and weekly performance of 164.32 percent. The stock has been moved at 76.20 percent over the last six months. The stock has performed 146.97 percent around the most recent 30 days and changed 89.40 percent over the most recent 3-months.
If compared to the average trading volume of 242.00K shares, NKTR reached to a volume of 36753778 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Nektar Therapeutics [NKTR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NKTR shares is $90.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NKTR stock is a recommendation set at 1.75. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Nektar Therapeutics shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 24, 2025. While these analysts kept the previous recommendation, BTIG Research dropped their target price from $60 to $100. The new note on the price target was released on June 24, 2025, representing the official price target for Nektar Therapeutics stock. Previously, the target price had yet another raise to $2, while Jefferies analysts kept a Buy rating on NKTR stock.
The Price to Book ratio for the last quarter was 22.08, with the Price to Cash per share for the same quarter was set at 17.62.
NKTR stock trade performance evaluation
Nektar Therapeutics [NKTR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 164.32. With this latest performance, NKTR shares gained by 146.97% in over the last four-week period, additionally plugging by 76.20% over the last 6 months – not to mention a rise of 75.27% in the past year of trading.
Nektar Therapeutics [NKTR]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Nektar Therapeutics [NKTR] shares currently have an operating margin of -160.27% and a Gross Margin at 74.12%. Nektar Therapeutics’s Net Margin is presently recorded at -152.49%.
Return on Equity for this stock declined to -40.79%, with Return on Assets sitting at -40.79%.
Earnings per share (EPS) analysis for Nektar Therapeutics [NKTR] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NKTR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Nektar Therapeutics go to -16.75%.
Nektar Therapeutics [NKTR]: Institutional Ownership
There are presently around $67.12%, or 68.00% of NKTR stock, in the hands of institutional investors. The top three institutional holders of NKTR stocks are: DEEP TRACK CAPITAL, LP with ownership of 17.88 million shares, which is approximately 8.5599%. BLACKROCK INC., holding 15.16 million shares of the stock with an approximate value of $$18.79 million in NKTR stocks shares; and BLACKROCK INC., currently with $$16.08 million in NKTR stock with ownership which is approximately 6.2097%.
